MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202531060153 A) filed by Kalinga Institute Of Industrial Technology Kiit Deemed To Be University on June 24, 2025, for Live-Attenuated Vaccine For Salmonella Typhimurium And Shigella Dysenteriae Infections.
Inventors include Mrutyunjay Suar; Gajraj Singh Kushwaha; and Saumya Darshana Patra.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: ABSTRACT LIVE-ATTENUATED VACCINE FOR SALMONELLA TYPHIMURIUM AND SHIGELLA DYSENTERIAE INFECTIONS The present invention relates to a live-attenuated bivalent vaccine for the prevention of Salmonella Typhimurium and Shigella dysenteriae infections. The vaccine is developed by constructing a chimeric polynucleotide encoding the B subunit of the Shigella toxin (StxB) into a pMS102 plasmid and transforming it into an attenuated Salmonella Typhimurium strain Z234. This recombinant strain elicits protective mucosal and systemic immune responses against both pathogens. The invention also discloses a method for preparing the vaccine using recombinant DNA technology, offering a safe, stable, and highly immunogenic solution to combat dual enteric infections.
Disclaimer: Curated by HT Syndication.
